576 related articles for article (PubMed ID: 32354198)
1. The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors.
Baci D; Bosi A; Gallazzi M; Rizzi M; Noonan DM; Poggi A; Bruno A; Mortara L
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32354198
[TBL] [Abstract][Full Text] [Related]
2. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract][Full Text] [Related]
3. Ovarian Cancer Immunotherapy: Turning up the Heat.
Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
5. Rationale for anti-CD137 cancer immunotherapy.
Makkouk A; Chester C; Kohrt HE
Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling.
Fix SM; Forget MA; Sakellariou-Thompson D; Wang Y; Griffiths TM; Lee M; Haymaker CL; Dominguez AL; Basar R; Reyes C; Kumar S; Meyer LA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35882447
[TBL] [Abstract][Full Text] [Related]
7. DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer.
Travers M; Brown SM; Dunworth M; Holbert CE; Wiehagen KR; Bachman KE; Foley JR; Stone ML; Baylin SB; Casero RA; Zahnow CA
Cancer Res; 2019 Jul; 79(13):3445-3454. PubMed ID: 31088836
[TBL] [Abstract][Full Text] [Related]
8. Biological effects of IL-15 on immune cells and its potential for the treatment of cancer.
Zhang S; Zhao J; Bai X; Handley M; Shan F
Int Immunopharmacol; 2021 Feb; 91():107318. PubMed ID: 33383444
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
[TBL] [Abstract][Full Text] [Related]
10. Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer.
Lakis S; Kotoula V; Koliou GA; Efstratiou I; Chrisafi S; Papanikolaou A; Zebekakis P; Fountzilas G
Cancer Genomics Proteomics; 2020; 17(5):529-541. PubMed ID: 32859631
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumor microenvironment in ovarian cancer: Premise and promise.
Jiang Y; Wang C; Zhou S
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188361. PubMed ID: 32234508
[TBL] [Abstract][Full Text] [Related]
12. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
[TBL] [Abstract][Full Text] [Related]
13. Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer.
Luo X; Xu J; Yu J; Yi P
Front Immunol; 2021; 12():692360. PubMed ID: 34248988
[TBL] [Abstract][Full Text] [Related]
14. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of the immune microenvironment in ovarian cancer patients.
Yang L; Wang S; Zhang Q; Pan Y; Lv Y; Chen X; Zuo Y; Hao D
Mol Omics; 2018 Oct; 14(5):341-351. PubMed ID: 30129640
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated macrophage-targeted therapeutics in ovarian cancer.
An Y; Yang Q
Int J Cancer; 2021 Jul; 149(1):21-30. PubMed ID: 33231290
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
18. Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.
Khairallah AS; Genestie C; Auguste A; Leary A
Int J Cancer; 2018 Jul; 143(1):8-15. PubMed ID: 29218796
[TBL] [Abstract][Full Text] [Related]
19. Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells.
Jiang L; Fang X; Wang H; Li D; Wang X
Front Immunol; 2018; 9():2927. PubMed ID: 30619288
[TBL] [Abstract][Full Text] [Related]
20. Histamine in cancer immunology and immunotherapy. Current status and new perspectives.
Sarasola MP; Táquez Delgado MA; Nicoud MB; Medina VA
Pharmacol Res Perspect; 2021 Oct; 9(5):e00778. PubMed ID: 34609067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
